Monday
07.15.2019
9:23 PM
Login form
Search
Calendar
Entries archive

Africa Live News

Main » 2015 » December » 15 » Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the S
2:23 PM
Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the S

 Integrated teams focusing research efforts in six core therapeutic areas including heart failure and oncology

KYOTO & OSAKA, Japan - Tuesday, December 15th 2015 [ME NewsWire]

(BUSINESS WIRE)-- The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint research program to develop clinical applications of induced pluripotent stem cells. The "Takeda-CiRA Joint Program for iPS Cell Applications" (T-CiRA) will begin research in six core directions to explore clinical applications of stem cells in therapeutic areas including cancer, heart failure, diabetes mellitus, neuro-degenerative disorders and intractable muscle diseases.

Induced pluripotent stem (iPS) cell technologies have the potential to bring about ground-breaking transformations to future medical treatments, and their applications span a variety of fields, including drug discovery, cell therapy and drug safety assessments. During the next 10 years, Takeda will provide collaborative funding of 20 billion yen, and will jointly run multiple projects led by researchers invited from CiRA and other universities. The collaboration is expected to make significant contributions to the application of iPSC technology into clinical practice, which requires a significant amount of time, effort and investment. It is aligned with the purpose of National Projects of Japan on clinical applications of iPS cell technologies.

"I am so happy to see that the six research groups, comprised of researchers from Takeda and CiRA, have been kicked off their research projects, with generous support from Takeda. Using iPSC technology as a tool, this collaboration will develop new approaches to drug discovery and produce new cures to intractable diseases over the next 10 years," said Shinya Yamanaka, M.D., Ph.D., director of CiRA, who is a Nobel laureate in 2012 for his work on iPS cells.

"Takeda is proud to be part of this important research program. Academic and research partnerships, particularly with renowned scientific institutions such as Kyoto University, are critical to advancing clinical knowledge and potential future applications that could improve patient lives," said Christophe Weber, President & CEO of Takeda. "This partnership also marks a new direction for Takeda, by exploring cell therapies and genetic strategies to avert and remedy disease."

Currently, six projects, described below, are carried out simultaneously at Takeda's Shonan Research Center (Kanagawa, Japan) as the main venue, with approximately 60 researchers in total from CiRA and Takeda.

"New projects will be added to the T-CiRA Program when the new laboratory space is completed in April, 2016," said Seigo Izumo, who is Global Head of Regenerative Medicine and Takeda's chief advisor to Professor Yamanaka. "It is anticipated that the Program will have over 10 projects with participation of more than 100 researchers at its steady state."

To view the table please click here.

About the Center for iPS Cell Research and Application at Kyoto University (CiRA) CiRA was established on April 1, 2010 to serve as the world’s first core institute dedicated to pioneering iPS cell research. With Dr. Shinya Yamanaka serving as Director, CiRA’s 30 research groups are engaged in fundamental science of cell reprogramming and human development, clinical applications, and bioethics, with the overall goal of using iPS cells to realize regenerative medicine and drug discovery. Additional information about CiRA is available through its website at www.cira.kyoto-u.ac.jp

About Takeda Pharmaceutical Company Limited Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Related materials Press release: CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research http://www.takeda.com/news/2015/20150417_6964.html T-CiRA website http://www.takeda.com/t-cira/

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51242793&lang=en

To view the full report and table please click here.

Contacts

Media contacts

Center for iPS Cell Research and Application at Kyoto University (CiRA)

Akemi Nakamura and Hiroyuki Wadahama, +81 (0)75-366-7005

International Public Communications Office

media@cira.kyoto-u.ac.jp

 

Takeda Pharmaceutical Company Ltd.

Japanese Media

Tsuyoshi Tada, +81 (0)3-3278-2417

tsuyoshi.tada@takeda.com

 

Media outside Japan

Jocelyn Gerst, +1 (224) 554-5542

jocelyn.gerst@takeda.com

 

 

 

Views: 92 | Added by: uaeonlinenews | Rating: 0.0/0
Total comments: 0
Name *:
Email *:
Code *: